Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma

Luise Eckardt1,2*, Maria Prange-Barczynska1,3*, Emma J Hodson4,5, James W Fielding1,3, Xiaotong Cheng1,3, Joanna D C C Lima1, Samvid Kurlekar1, Gillian Douglas6, Peter J Ratcliffe1,3,4 and Tammie Bishop1*

1Target Discovery Institute, University of Oxford, Oxford, UK
2Institute of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany
3Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK
4The Francis Crick Institute, London, UK
5The Department of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK
6BHF Centre of Research Excellence, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK

Correspondence should be addressed to P J Ratcliffe or T Bishop: peter.ratcliffe@ndm.ox.ac.uk or tammie.bishop@ndm.ox.ac.uk

*(L Eckardt and M Prange-Barczynska contributed equally to this work)

Abstract

Despite a general role for the HIF hydroxylase system in cellular oxygen sensing and tumour hypoxia, cancer-associated mutations of genes in this pathway, including PHD2, PHD1, EPAS1 (encoding HIF-2α) are highly tissue-restricted, being observed in pseudohypoxic pheochromocytoma and paraganglioma (PPGL) but rarely, if ever, in other tumours. In an effort to understand that paradox and gain insights into the pathogenesis of pseudohypoxic PPGL, we constructed mice in which the principal HIF prolyl hydroxylase, Phd2, is inactivated in the adrenal medulla using TH-restricted Cre recombinase. Investigation of these animals revealed a gene expression pattern closely mimicking that of pseudohypoxic PPGL. Spatially resolved analyses demonstrated a binary distribution of two contrasting patterns of gene expression among adrenal medullary cells. Phd2 inactivation resulted in a marked shift in this distribution towards a Pnmt−/Hif-2α+Rgs5+ population. This was associated with morphological abnormalities of adrenal development, including ectopic TH+ cells within the adrenal cortex and external to the adrenal gland. These changes were ablated by combined inactivation of Phd2 with Hif-2α, but not Hif-1α. However, they could not be reproduced by inactivation of Phd2 in adult life, suggesting that they arise from dysregulation of this pathway during adrenal development. Together with the clinical observation that pseudohypoxic PPGL manifests remarkably high heritability, our findings suggest that this type of tumour likely arises from dysregulation of a tissue-restricted action of the PHD2/HIF-2α pathway affecting adrenal development in early life and provides a model for the study of the relevant processes.

Key Words

- PHD
- HIF
- hypoxia
- adrenal medulla
- pheochromocytoma
Introduction

Pheochromocytoma and paraganglioma (PPGL) are tumours of the autonomic paraganglia that arise in diverse anatomical locations from the skull base to the pelvis. Those found within the adrenal glands (AGs) are known as pheochromocytoma (PCC) and those in extra-adrenal structures including the carotid body are commonly termed paraganglioma (PGL). Molecular analysis of these tumours has revealed a number of subtypes or clusters, with distinct patterns of gene expression within the tumour being associated with different groups of tumour-associated mutations. Genetic profiling has revealed four such subtypes: kinase signalling, Wnt-altered, cortical admixture and pseudohypoxia (Crona et al. 2017, Fishbein & Wilkerson 2018). The pseudohypoxia subtype (or Cluster I) is associated with mutations affecting transcriptional pathways induced by hypoxia.

The transcriptional response to hypoxia is mediated by hypoxia-inducible factor (HIF) (reviewed in Bishop & Ratcliffe 2014), a heterodimer consisting of an oxygen-regulated α and a constitutively expressed β subunit. HIF-α is regulated by a series of 2-oxoglutarate-dependent dioxygenases that generate an oxygen-dependent signal by hydroxylation of specific prolyl residues in HIF-α subunits which are targeted for proteasomal degradation via the E3 ubiquitin ligase von Hippel-Lindau (VHL) protein. Mammalian species have multiple HIF-α isoforms, of which HIF-1α and HIF-2α are the most abundant and best studied. They also express three closely related isoforms of the HIF prolyl hydroxylase enzymes (PHD1, PHD2 and PHD3, otherwise known as EGLN2, EGLN1 and EGLN3), of which PHD2 is the most abundant and important regulator of HIF.

HIF is commonly activated in cancer and its role in oncogenesis has attracted widespread interest, particularly in view of the recent development of drugs with the potential to activate or inactivate components of the pathway therapeutically (reviewed in Semenza 2019, Choueiri & Kaelin 2020). Nevertheless, this relationship of HIF activation to oncogenesis has proved more complex than anticipated. For instance, although HIF is commonly upregulated in cancer, direct genetic activation by mutation of any of the key components of the pathway is rare in most forms of cancer.

The pseudohypoxic subtype of PPGLs is an important exception. These tumours manifest a ‘pseudohypoxic’ pattern of gene expression encompassing upregulation of certain HIF target genes, together with alterations in the expression of differentiation markers (Dahia et al. 2005, Favier et al. 2009, 2012, Waldmann et al. 2010, Burnichon et al. 2011, Lorenzo et al. 2013, Toledo et al. 2013, Welander et al. 2014, Yang et al. 2015, Fishbein et al. 2017). They are associated with loss-of-function mutations in VHL, PHD2 and PHD1 and gain-of-function mutations in HIF-2α (otherwise known as EPAS1) as well as mutations in genes encoding the tricarboxylic acid cycle enzymes succinate dehydrogenase (SDHB/D/C/A or SDHx) and fumarate hydratase (FH) (Dahia et al. 2005, Ladr Rouge et al. 2008, Zhuang et al. 2012, Yang et al. 2015). Impaired function of the latter two enzymes leads to the accumulation of succinate and fumarate, respectively, which are able to inhibit 2-oxoglutarate-dependent dioxygenases including the HIF prolyl hydroxylases. All these mutations therefore have the potential to activate HIF, suggesting that in this setting it is HIF that provides the oncogenic drive.

However, there are a number of puzzling features in these associations. First, PPGLs in general manifest an unusually high ratio of inherited to sporadic forms. For instance, up to 40% of PPGLs are associated with germline or post-zygotic but very early somatic mutation, as assessed by family history or distribution of mutant cells (Buffet et al. 2020). Secondly, the spectrum of gene dysregulation in pseudohypoxic PPGLs does not align exactly with that of dynamically regulated HIF transcriptional targets (Dahia et al. 2005, Favier et al. 2009, 2012, Waldmann et al. 2010, Burnichon et al. 2011, Lorenzo et al. 2013, Toledo et al. 2013, Welander et al. 2014, Yang et al. 2015, Fishbein et al. 2017). Thirdly, human VHL mutations associated with PCCs have a complex relationship to dysregulation of HIF: type 1 VHL mutations, which show complete dysregulation of HIF, are not associated with pheochromocytoma whereas type 2A, B and C VHL mutations, which are associated with pheochromocytoma, show either less severe or no dysregulation of HIF, at least when assayed in vitro or in heterologous cell types (Kaelin 2008). Fourthly, Vhl inactivation in the adrenal medulla (AM) and carotid body of the mouse results in tissue atrophy rather than tumour formation (Macias et al. 2014).

In an attempt to shed light on these paradoxical findings and better understand the role of activation of HIF pathways in the AM, we have examined the effects of inactivation of the principal HIF prolyl hydroxylase Phd2 in the AM, using Cre recombinase restricted by the tyrosine hydroxylase (TH) promoter, in the mouse. We report that TH-restricted constitutive inactivation of Phd2 in the AM results in a ‘pseudohypoxic pattern’ of gene expression in which dynamic activation of HIF transcription is superimposed on a developmental shift in populations of AM cells manifesting specific patterns of
gene expression associated with the presence or absence of phenylethanolamine N-methyltransferase (PNMT). Changes in gene expression were accompanied by morphological abnormalities including ectopic TH+ cells within the adrenal cortex and in peri-adrenal structures. These findings, together with marked differences between constitutive and inducible inactivation of Phd2 in adult life, suggest that the pathological activation of the PHD2/HIF-2 pathway during adrenal development is critical for its tumourigenic action.

Methods

Ethical approval and animals

Animal experimental protocols were approved by the University of Oxford Medical Science Division Ethical Review Committee and are compliant with the UK Home Office Animals (Scientific Procedures) Act 1986. Experiments were performed on ~3 month-old mice and sex-matched controls, unless stated otherwise. Mice were kept in individually ventilated cages with free access to water and food. Phd2f/f, Hif-1a+/− and Hif-2α+/− alleles are as described (Cramer et al. 2003, Gruber et al. 2007, Mazzone et al. 2009). Note that Phd2 is equivalent to Egln1 and Hif-2α is equivalent to Epas1; we have used the Phd2/Hif-2α terminology to simplify mechanistic interpretation for the reader. TH+ cell-specific inactivation was achieved using the constitutively expressed TH-IRES-Cre (THCre; Lindeberg et al. 2004) or inducible TH-IRES-CreER (THCreER; Rotolo et al. 2008) and ubiquitous inactivation using the inducible Rosa26CreERT2 (RosaCreER; Vooijs et al. 2001). Each mouse line was backcrossed with C57BL/6 for at least five generations.

Drug administration

For adult-onset Phd2 inactivation, ~6 week-old mice were dosed once daily with 2 mg tamoxifen orally (20 mg/mL in corn oil containing 10% ethanol, Sigma) for 5 consecutive days. Phd2f/f;RosaCreER and Phd2f/f;THCreER mice were sacrificed 17 days or ~3 months, respectively, after the start of treatment.

Tissue collection

Animals were killed by an overdose of isoflurane (Piramal Critical Care, West Drayton, UK) and exsanguination from the inferior vena cava. Blood was collected using heparinised needles. AGs for RT-qPCR were dissected into ice-cold phosphate buffered saline (PBS, in mM: 137 NaCl, 2.7 KCl, 4 Na2HPO4·7H2O, 1.5 KH2PO4) in diethyl pyrocarbonate-treated water (0.1%, v/v, Sigma). For histology, mice were perfused-fixed with 5 mL PBS followed by 5 mL 4% paraformaldehyde (PFA)/PBS (w/v) (Sigma). Dissected AGs were fixed in 4% PFA/PBS overnight, transferred into 70% (v/v) ethanol then dehydrated in an ascending ethanol series ending in histoclear (National Diagnostics, Atlanta, US), embedded in 60°C paraffin and sectioned to 4 μm thickness with a Microm HM 355S microtome (Thermo Fisher Scientific).

Catecholamine measurements

Blood was centrifuged at 800 g for 5 min and plasma was separated and stored at −80°C. Adrenaline and noradrenaline were detected in diluted plasma samples using the Epinephrine/Norepinephrine ELISA Kit (KA1877, Abnova, Taoyuan City, Taiwan). Signal absorbance was read at 450 nm using a FLUOstar Omega microplate reader (BMG Labtech, Aylesbury, UK). Catecholamine concentrations were calculated using a linear standard curve.

Immunohistochemistry

Sections were immunostained for TH using an EnVision+ kit (Dako Denmark A/S) with a polyclonal rabbit anti-TH antibody (1:5000, NB300-109, Novus Biologicals, Cambridge, UK) (Bishop et al. 2013).

In situ hybridisation

mRNA was detected in sections using the manual RNAscope 2.5 HD BROWN assay or, for dual in situ hybridisation, the RNAscope 2.5 HD Duplex assay (Advanced Cell Diagnostics, Newark, US). RNAscope probes: Mm-Pnmt (426421 or 426421-C2 for dual RNAscope), Mm-Epas1 (314371), Mm-Rgs5 (430181), Mm-Vegfa-OI (43961). Imaging was performed with a Leica DM 1000 LED microscope (Leica Biosystems).

Proximity ligation in situ hybridisation (PLISH)

Multiplex fluorescence in situ hybridisation was performed using PLISH (Nagendran et al. 2018). Sections were de-paraffinised, boiled in a 10 mM citrate buffer (pH 6.0) with 0.05% lithium dodecyl sulfate (Sigma) and processed in sealed hybridisation chambers (Grace Biolabs, Bend, US). Tissues were treated with...
0.1 mg/mL Pepsin (Roche-10108507001, Sigma-Aldrich) in 0.1 M HCl, followed by (at 37°C): hybridisation of barcoded gene probes and bridge sequences, DNA ligation (10 CEU/mL T4 DNA ligase, M0202T, New England Biolabs, Ipswich, MA) and extension by rolling circle amplification (1 U/mL Nxs29 polymerase, Lucigen, Middleton, WI). Samples were incubated with fluorophore-conjugated oligonucleotides specific to the barcode for the targeted gene probe (Supplementary Methods, see section on supplementary materials given at the end of this article), washed then treated with TruVIEW autofluorescence quenching kit (Vector Laboratories, Burlingame, MA), stained with DAPI and mounted. Imaging was performed with a Zeiss Axioskop 2 plus microscope (Jena, Germany) and analysed with Qupath software (Bankhead et al. 2017).

**Morphometric analysis**

AM volume was modelled by measuring the TH+ area of one in eight consecutive slides of the AM using ImageJ software (NIH) (Bishop et al. 2008, Fielding et al. 2018). In situ hybridisation signal was quantified using trainable Weka segmentation plugin in Fiji ImageJ 1.53c software (NIH) (Cheng et al. 2020).

**RT-qPCR**

AGs were collected from five mice per genotype and AMs sub-dissected under an SMZ-745 stereo microscope (Nikon) and stored in RNAProtect (Qiagen) on ice. Pooled tissues were homogenised in RLT+ buffer (Qiagen) using a ProScientific PRO200 Homogenizer (Cole-Parmer, Eaton Socon, UK). RNA was isolated using the RNeasy Plus Micro Kit (Qiagen), cDNA prepared using the Quantitect RT Kit (Qiagen) and RT-qPCR performed with the TaqMan Fast Advanced Master Mix Kit (Thermo Fisher Scientific) in the StepOnePlus Real-Time PCR System (Applied Biosystems). Three technical replicates were used in each biological repeat with Actb serving as a reference gene (see Supplementary methods for TaqMan probes). Fold change in gene expression was reported as 2−ΔΔCt, where ΔΔCt = Phd2+/−;THCre (Ct_target − Ct_reference) − Phd2+/− (Ct_target − Ct_reference).

**Statistical analysis**

Data are shown as mean ± S.E.M. Statistical analyses were performed using unpaired Student’s t-tests, unless otherwise stated, and using GraphPad Prism 9.0 Software.

**Results**

Since pseudohypoxic PPGLs have a characteristic gene expression profile, we first sought to test whether and to what extent this was mimicked by Phd2 inactivation in the AM. To this end, we intercrossed mice bearing a conditionally inactivated (Phd2+/−) allele with a transgenic line expressing Cre recombinase restricted by the TH promoter (THCre) to generate Phd2+/−;THCre mice and measured effects on the expression of a panel of 14 genes that are frequently dysregulated in pseudohypoxic PPGLs (Supplementary Table 1). This comprised several classes of genes, including HIF target genes Vegfa, Scl2a1 and Ldha; atypical mitochondrial subunits Ndufa4l2 and Cox4l2; G-protein signalling pathway components Rgs4, Rgs5 and Adora2a; Pnmt, the terminal enzyme in catecholamine synthesis; genes with oncogenic potential including Stc1.

These experiments revealed that many, though not all, genes identified as dysregulated in pseudohypoxic PPGLs were also dysregulated in a similar way in the AM of Phd2+/−;THCre mice (Fig. 1A), suggesting that their expression is directly or indirectly altered as a consequence of dysregulation of the PHD2/HIF system in this setting. Interestingly, not all these genes have been identified as being dynamically regulated by HIF itself in the manner observed. In particular, Pnmt has been reported to be upregulated by HIF-1 in rat pheochromocytoma PC12 cells (Tai et al. 2009), whereas we observed striking downregulation of Pnmt (mRNA and protein) with Phd2 inactivation/HIF activation (Fig. 1A and Supplementary Fig. 1). PNMT is the terminal enzyme in the catecholamine synthesis pathway which converts noradrenaline into adrenaline. In keeping with the loss of Pnmt, we observed a shift in plasma catecholamines: an increase in noradrenaline together with a reduction in adrenaline (Fig. 1B). This predominantly noradrenergic secretory profile, together with a loss of Pnmt expression, is similar to clinical observations in patients with pseudohypoxic PCCs (Eisenhofer et al. 2001).

We therefore sought to determine whether Phd2+/−;THCre mice have morphological features of PCC, in particular evidence of intra-adrenal pathology. However, no frank tumours, nodules, cortical compression or loss of nest-like/formation of sheet-like chromaffin cell clusters (Smith-Hicks et al. 2000, Park et al. 2015) were observed, and there was no change in overall AM volume or proliferation (Supplementary Table 2).

However, we noted striking abnormalities of adrenal morphology, in particular the abnormal location of TH+ cells. These comprised clusters of ectopic cells in the
adrenal cortex that disrupt the outer cortical boundary, adjacent to a TH+ extra-adrenal ganglion-like structure (Fig. 1C). Altogether, 11 out of 14 Phd2f/f;THCre mice and 0 out of 15 littermate controls manifest these abnormalities.

TH+ chromaffin cells migrate through the adrenal cortex to reach their final destination in the AM (Furlan et al. 2017, Hanemaaijer et al. 2021), during which time they acquire Pnmt expression in the final stages of maturation to become adrenergic (Verhofstad et al. 1979). We therefore considered whether the abnormally located TH+ cells (both within and directly adjacent to the AG) represent abnormal migration of chromaffin cells and that the reduction in Pnmt might also reflect failure to acquire Pnmt due to dysregulated/ arrested development with Phd2 inactivation.

To address this, we proceeded to analyse the spatial distribution of gene expression within the AM. The normal AG is known to express Pnmt in a restricted set of mature chromaffin cells that produce adrenaline (Coupland & Hopwood 1966). Analysis of the spatial distribution of Pnmt expression in WT mice confirmed this, with the majority (~75%) of chromaffin cells expressing Pnmt (Fig. 2A). We next considered whether this expression pattern extended to other genes which were dysregulated in AMs with loss of Phd2. The following genes were selected for analysis: Hif-2α, since its upregulation is characteristic of VHL-associated neoplasia including PCCs (Toledo 2017); Vegfa and Rgs5, since these are reported HIF target genes (Jin et al. 2009, Fielding et al. 2018) and the latter is also a proposed regulator of chromaffin cell differentiation (Chan et al. 2019, Hanemaaijer et al. 2021). These experiments revealed a striking inverse pattern of gene expression, with Hif-2α and Rgs5 mRNA being expressed...
**Figure 2**

Effect of *Phd2* inactivation on the spatial expression of genes in the AM. (A) *In situ* hybridisation for *Pnmt*, *Hif-2α*, *Rgs5* and *Vegfa* mRNA (brown) in adjacent sections of a WT AG showing *Hif-2α* and *Rgs5* mRNA expression in *Pnmt*+ cells. Gill’s haematoxylin counterstain (grey-blue). Scale bars: 0.2 mm. (B) Comparison of *Pnmt*, *Hif-2α*, *Rgs5* and *Vegfa* mRNA expression in *Phd2fl/fl* vs *Phd2fl/fl;THCre* AMs. Red dashed lines outline *Pnmt*/Hif-2α*/Rgs5* cell populations in this and other figures. Images show a switch from predominantly *Pnmt*/Hif-2α*/Rgs5* to *Pnmt*/Hif-2α*/Rgs5* cells following *Phd2* inactivation. Harris haematoxylin counterstain (blue). Scale bars: 0.1 mm.
only in the normal AM cells that do not express \textit{Pnmt} (Fig. 2A). \textit{Vegfa}, on the other hand, could not be detected, except in the adrenal cortex where it was strongly expressed (Fig. 2A). This suggested the possibility that a binary, cell-specific pattern of expression exists within AM cells, with low \textit{Pnmt} associating with high \textit{Hif}-2\textalpha and upregulation of at least some of its transcriptional targets such as \textit{Rgs5}.

The findings therefore raised the interesting question as to whether inactivation of \textit{Phd2} might affect the expression of these genes (\textit{Pnmt}, \textit{Hif}-2\textalpha, \textit{Rgs5} and \textit{Vegfa}) within a specific population of cells or whether the prevalence of the two populations manifesting the observed patterns of gene expression might change after \textit{Phd2} inactivation. To address this, we performed further \textit{in situ} mRNA hybridisation studies. These studies revealed a major switch of cell populations in AMs following \textit{Phd2} inactivation. The same pattern of \textit{Pnmt}−/\textit{Hif}-2\textalpha+/\textit{Rgs5}− was maintained, but cells manifesting this pattern now became the dominating cell population distributed across most of the AM with the exception of small areas around the periphery (Fig. 2B). Within the dominating population of \textit{Pnmt}−/\textit{Hif}-2\textalpha+/\textit{Rgs5}+ expressing cells, there was also a mild induction of the HIF target gene \textit{Vegfa} (Fig. 2B).

This inverse expression of \textit{Pnmt} and \textit{Hif}-2\textalpha/\textit{Rgs5}/\textit{Vegfa} in \textit{Phd2}+/− and \textit{Phd2}+/−/THCre AMs was confirmed by \textit{in situ} hybridisation and PLISH, which allow multiplexing of different mRNA probes to measure overlapping patterns of expression (Fig. 3 and Supplementary Fig. 2).

We next went on to examine the ectopic TH+ cells within the adrenal cortex. Interestingly, essentially

![Figure 3](https://doi.org/10.1530/ERC-21-0211)

Spatial co-localisation of genes in the AM. (A) Dual \textit{in situ} hybridisation or (B) proximity ligation \textit{in situ} hybridisation (PLISH) for \textit{Pnmt}, \textit{Hif}-2\textalpha, \textit{Rgs5} and \textit{Vegfa} mRNA in \textit{Phd2}+/− and \textit{Phd2}+/−/THCre AMs. \textit{Pnmt} expression in cells inversely correlates with \textit{Hif}-2\textalpha and \textit{Rgs5} in both genotypes but \textit{Pnmt}+/−/\textit{Hif}-2\textalpha+/\textit{Rgs5}− cell populations are dominant in \textit{Phd2}+/− whereas this switches to \textit{Pnmt}−/\textit{Hif}-2\textalpha+/\textit{Rgs5}− cells in \textit{Phd2}+/−/THCre AMs, which additionally show induction of \textit{Vegfa}. For dual \textit{in situ} hybridisation, Gill's haematoxylin counterstain (grey-blue). Scale bars for dual \textit{in situ} hybridisation: 0.1 mm, for PLISH: 0.05 mm.
all these cells were \textit{Pnmt}±\textit{Hif-2α}/\textit{Rgs5}±\textit{Vegfa} (Fig. 4) (and negative for the adrenal cortical cell marker \textit{Cyp11a1}, Supplementary Fig. 3), again suggestive of arrested migration of an immature \textit{Pnmt}− population of chromaffin cells within the adrenal cortex during development. Taken together, these experiments suggest that TH-restricted \textit{Phd2} inactivation results in a pattern of gene expression similar to that of pseudohypoxic PPGLs. Morphological abnormalities suggestive of an effect on adrenal development were coupled to a major switch in an apparently binary pattern of gene expression observed in populations of cells within the AM.

To further understand this process, we intercrossed animals to generate \textit{Phd2}−/−;\textit{Hif-1α}−/−;\textit{THCre} and \textit{Phd2}−/−;\textit{Hif-2α}/−;\textit{THCre} mice, which were examined with respect to the above phenotypes. No reversion of the morphological phenotype was observed with concomitant \textit{Hif-1α} inactivation (Fig. 5). In striking contrast, \textit{Hif-2α} inactivation (\textit{Phd2}−/−;\textit{Hif-2α}/−;\textit{THCre} mice) completely reversed all the morphological abnormalities associated with \textit{Phd2} inactivation, such that AMs were similar to those of control (\textit{Phd2}−/−) mice (Fig. 5). Similar results were obtained with analysis of \textit{Pnmt}, \textit{Rgs5} and \textit{Vegfa} gene expression. The inverse expression pattern of \textit{Pnmt} and \textit{Rgs5} was invariant, but the proportion of cells of each type was strikingly different, with \textit{Phd2}−/−;\textit{Hif-1α}−/−;\textit{THCre} mice retaining a dominant population of \textit{Pnmt−}/\textit{Rgs5}+ cells while \textit{Phd2}−/−;\textit{Hif-2α}/−;\textit{THCre} mice apparently reverted to a phenotype indistinguishable from controls, including loss of \textit{Vegfa} mRNA (Fig. 5). Together, this indicates that \textit{Hif-2α}, not \textit{Hif-1α}, is necessary for the abnormal phenotype resembling pseudohypoxic PCCs.

We therefore hypothesised that inactivation of \textit{Phd2} might have at least two distinct effects in order to generate this pseudohypoxic phenotype: first, a dynamic induction of HIF transcriptional target genes including \textit{Vegfa}; secondly, a switch to an immature noradrenergic cellular phenotype within the AM. Since we also observed morphological abnormalities suggestive of interrupted differentiation and/or migration, we sought to determine whether these components of the pseudohypoxic phenotype might reflect an action of the PHD2/HIF-2 axis during differentiation. To test this, we proceeded to compare the effects with those in animals where inactivation of \textit{Phd2} was restricted to adult life, using two different models. We analysed adult \textit{Phd2}−/−;\textit{THCreER} at 3 months after inducing recombination with tamoxifen. To assess any effect of more extensive recombination, adult \textit{Phd2}−/−;\textit{RosaCreER} mice were also studied. Since these develop systemic abnormalities (Hodson \textit{et al.} 2016), they were studied somewhat earlier, approximately 17 days after tamoxifen dosing.

In striking contrast to \textit{Phd2}−/−;\textit{THCre} mice, inactivation of \textit{Phd2} in adult mice by either protocol did not result in morphological abnormalities or a change in the spatial distribution of \textit{Pnmt}− and \textit{Pnmt}+ cells (Fig. 6). Additionally, no change in AM volume or proliferation was noted (Supplementary Table 2). In contrast, induction of \textit{Rgs5} and \textit{Vegfa} mRNA was observed in both models of adult-onset \textit{Phd2} inactivation and was apparently confined to the population of cells that did not express \textit{Pnmt} and were \textit{Hif-2α} (Figs 6, 7 and Supplementary Fig. 4). Together, this suggests that two distinct effects of HIF-2 activation contribute to the pseudohypoxic phenotype observed with TH-restricted \textit{Phd2} inactivation: first, as a regulator of chromaffin cell differentiation during development; secondly, as a dynamic regulator of HIF target gene expression within \textit{Hif-2α} expressing cells.

**Discussion**

Our findings demonstrate that TH-restricted inactivation of \textit{Phd2} results in a pattern of gene expression within the AM that resembles pseudohypoxic PPGLs. Importantly, several lines of evidence reveal that in addition to dynamic activation of the HIF transcriptional response, this alteration in gene expression reflects developmental consequences of \textit{Phd2} inactivation on the AM. First, the alteration in gene expression involves spatial changes in cell-specific patterns of gene expression that reflect lack of terminal differentiation to \textit{Pnmt}+ cells. Secondly, several of the genes involved in the altered pattern of expression, including \textit{Pnmt} and \textit{Hif-2α} itself, are not dynamic HIF transcriptional targets. Thirdly, altered patterns of gene expression were associated with morphological abnormalities, including ectopic TH+ cell populations with a \textit{Pnmt}− pattern of gene expression. Finally, neither the spatial change in gene expression within the AM nor the morphological abnormalities in the position of TH+ cells could be induced by \textit{Phd2} inactivation in adult life.

These findings are of particular interest when considered alongside several unusual observations on the clinical genetics of PPGL. Mutations that directly affect components of the PHD-HIF system are frequently observed in the uncommon syndrome of pseudohypoxic PPGL, but rarely, if ever, seen in other much more common forms of cancer. This is surprising since dynamic regulation of the transcriptional response
Figure 4
Gene expression profile of the ectopic TH⁺ cell tracks in adrenal glands from Phd2⁺/⁻;THCre mice. Representative images of ectopic TH⁺ cells in the adrenal cortex from two different adrenal glands (left vs middle and right hand columns) from Phd2⁺/⁻;THCre mice showing TH protein and Pnmt, Hif-2α, Rgs5 and Vegfa mRNA. TH⁺ cells in these ectopic tracks are essentially all Pnmt⁻/Hif-2α⁺/Rgs5⁺/Vegfa⁺. Harris haematoxylin counterstain (blue). Scale bars: 0.05 mm (left column), 0.5 mm (middle column), 0.2 mm (right column).
to hypoxia by the PHD-HIF system is a general function observed in all cells. In addition, pseudohypoxic PPGL is associated with a very much higher incidence of germline (or post-zygotic but early somatic) mutations vs sporadic mutations, as compared to other forms of neoplasia.

Our findings suggest a mechanism by which these apparently paradoxical findings could be explained. Specifically, the observation that dysregulation of the PHD-HIF system has a tissue-specific action on AM development suggests that these tumours have origins in early life, with
Figure 6
Effect of adult-onset Phd2 inactivation on morphology and gene expression in the AM. (A) Representative images of TH protein and Pnmt and Rgs5 mRNA in adrenal glands from Phd2\(^{-}\)THCreER, Phd2\(^{-}\)RosaCreER (and their respective Phd2\(^{+}\) controls) killed ~3 months or 17 days post tamoxifen treatment, respectively. Harris haematoxylin counterstain (blue). Scale bars: 0.5 mm (top row) or 0.2 mm (bottom two rows). (B) Quantification of the percentage of Pnmt\(^{+}\) and Rgs5\(^{+}\) AM area; AMs from Phd2\(^{-}\)THCre, Phd2\(^{-}\)THCreER and Phd2\(^{-}\)RosaCreER mice (filled bars and rhombi) and their respective controls (open bars and rhombi). Bars show mean ± s.e.m. Data within individual genotype groups were compared by unpaired two-tailed Student’s t-tests: \(*P < 0.05, **P < 0.01, ****P < 0.0001\). Adult-onset Phd2 inactivation did not phenocopy morphological abnormalities or Pnmt loss in the AM observed with early-onset Phd2 inactivation, although a small but significant induction in Rgs5\(^{+}\) was noted within the Pnmt\(^{-}\) cells of Phd2\(^{-}\)THCreER AMs.
PHD2-dependent cell differentiation changes predisposing to subsequent tumorigenesis. Interestingly, inactivation of the related HIF prolyl hydroxylase isofom PHD3 prevents developmental culling of neurons, and this has also been proposed to pre-dispose to tumours (Lee et al. 2005, Bishop et al. 2008). Consistent with the relevance of our findings to the human syndrome, we found that changes in adrenal morphology and gene expression were ablated by inactivation of Hif-2α, but not Hif-1α, in line with the observation that activating mutations in HIF-2α, but not...
HIF-1α are associated with human PPGL (Buffet et al. 2020). The finding of extra-adrenal tissue reported in our study might also be relevant to the not infrequent occurrence of chromaffin cell tumours at extra-adrenal sites (Tischler 2008). Although a correlation between the distribution of chromaffin tissue and paraganglioma has been reported (Coupland 1965), our data raises the possibility that these extra-adrenal PGLs may arise due to impaired migration and differentiation of sympathetic precursors that would normally populate the adrenal primordia to acquire features of mature, adrenergic chromaffin cells during development (Furlan et al. 2017, Hanemaaijer et al. 2021).

The precise action of HIF-2 in promoting abnormal adrenal development will require further investigation, including the dissection of effects on differentiation, migration and interaction with other processes including innervation (Vollmer 1996). Notably, inactivation of Hif-2α in the setting of Phd2 inactivation (Supplementary Fig. 5) did not obliterate Pmnt−/Rgs5− cells in Phd2f/f;Hif-2αf/f; THCre mice. Furthermore, in the normal AM, Pmnt− cells that show increased Hif-2α and Rgs5 mRNA levels did not express detectable levels of HIF-2α protein (data not shown). Thus, in this cell population, HIF-2 does not appear necessary to generate a Pmnt−/Hif-2α−/Rgs5− or noradrenergic phenotype; nor is HIF-2 necessary for PNMT acquisition in adrenergic cells, as evidenced from the normal AMs in Hif-2α−/Hif-2α− mice (Macias et al. 2018) as well as in Phd2f/f;Hif-2αf/f; THCre mice reported here. Rather, excess stabilisation of HIF-2α acts in some way to interrupt a developmental programme that ordinarily generates Pmnt+ in other AM cells.

Although Phd2 inactivation resulted in changes characteristic of pseudohypoxic PCCs, in this model we did not detect frank PCCs in ~3 month-old mice. Since PCC development might have a longer latency, we also analysed older cohorts of animals but again did not observe PCC development in n = 7 Phd2f/f;THCre and littermate control mice analysed aged ~18 months. However, we did observe three TH+, chromogranin A+ nodules of chromaffin cells amongst a group of n = 11 Phd2f/f;Hif-1af/f; THCre mice aged in parallel (Supplementary Fig. 6). The significance of this is unclear, but HIF-1α has been reported to act as a tumour suppressor in VHL-associated renal clear cell carcinoma (Shen et al. 2011), and it may be that HIF-1 also has a tumour suppressive role in this context.

Our findings have relevance for both experimental and clinical research into PCC. They suggest that it may also be useful to revisit mouse models of pseudohypoxic PCC including models of inactivation of Sdhx that have not resulted in PCC (Piruat et al. 2004, Bayley et al. 2009, Diaz-Castro et al. 2012, Macias et al. 2014, Lepoutre-Lussey et al. 2016, Al Khazal et al. 2021), to assess whether a switch from Pmnt−/Hif-2α−/Rgs5− to Pmnt−/Hif-2α−/Rgs5+ cell populations also occurs in these settings. At the clinical level, our findings suggest that attempts at prevention or treatment should rationally include a focus on early life. Interestingly, patients with congenital cyanotic heart disease (a condition associated with life-long hypoxaemia beginning perinatally) have been reported to be susceptible to PCCs, many of which harbour sporadic HIF-2α mutations (Opotowsky et al. 2015, Vaidya et al. 2018); our data suggests that it is the early-onset hypoxia in these patients which predisposes to subsequent PCC formation.

Interestingly, the HIF-2-dependent effects of Phd2 inactivation, including paraganglioma-like carotid bodies (Fielding et al. 2018), are strikingly different from those of Vhl inactivation in catecholaminergic tissues using the same THCre promoter as in this study, which results in atrophy of multiple organs of the sympathetic nervous system, including the AM and the carotid body (Macias et al. 2014). There is a complex association between mutations in VHL disease and the tumour phenotypes, with type 2 VHL mutations that result in PCCs having only modest (or minimal) effects on HIF dysregulation, while type 1 mutations do not develop PCCs and result in greater HIF stabilisation (Kaelin 2008). Although levels of HIF activation have not been compared directly, our findings support the hypothesis that more moderate HIF activation associated with inactivation of a single PHD (as opposed to another function of VHL distinct from an action on HIF) is the most likely explanation for this paradox.

Several other aspects of the dysregulated gene expression pattern merit comment. In particular, several genes that were upregulated in Phd2-inactivated AMs (including Rgs5, Cox4i2 and Adora2a) are very highly and specifically expressed in normal carotid body type I cells (Zhou et al. 2016), a cell type that responds to low oxygen with the rapid release of neurotransmitters to mediate hypoxic ventilatory control in what is termed acute oxygen sensing (Gao et al. 2019). Chromaffin cells are also reportedly acutely oxygen-sensitive during development, but this is lost in adulthood (Thompson et al. 1997). The retention of an immature phenotype in AMs with Phd2 inactivation may extend beyond gene expression to include retention of acute oxygen sensitivity. In future studies, it will be of interest to determine the extent to which Phd2 inactivation in the AM recreates oxygen sensitivity in the adult.
Supplementary materials

This is linked to the online version of the paper at https://doi.org/10.1530/ERC-21-0211.

Declaration of interest

P J R is a scientific co-founder of, and holds equity in, ReOx Ltd, a University spin-out company that seeks to develop therapeutic HIF hydroxylases inhibitors and a non-executive director of Immunocore Holdings PLC. E J H is employed under the Cambridge Experimental Medicine Initiative, partly funded by AstraZeneca, although they have not been involved in this project. The other authors declare no financial interests.

Funding

Funding for the work was received from the Oxford Branch of the Ludwig Institute for Cancer Research, the Wellcome Trust (106241/Z/14/2) and the Paradifference Foundation. This work was also supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001501), the UK Medical Research Council (FC001501), and the Wellcome Trust (FC001501). L E was sponsored by an MD fellowship from Boehringer Ingelheim Fonds; J D C C L by a FAPESP fellowship (2018/20083-1); S K by a Christopher Welch Scholarship and the Clarendon Fund.

Author contribution statement

Experiments were designed by L E, M P B, P J R and T B. Data were collected and analysed by all authors. Manuscript was prepared by L E, M P B, P J R and T B and reviewed by all authors. Figures were prepared and statistical analyses performed by L E and M P B with input from other authors. P J R and T B conceived the study and managed the project. P J R and T B are co-senior authors.

Acknowledgement

The authors thank Douglas Dos Santos Passos and Jade Harris for their help in various forms.

References


The role of PHD2 in pseudohypoxic PCCs

L Eckardt, M Prange-Barczynska et al.

Endocrine-Related Cancer

Received in final form 1 September 2021
Accepted 20 September 2021
Accepted Manuscript published online 20 September 2021


